Prospective CYP2C19 ‐Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations-Reference-Cited by-同舟云学术

Prospective CYP2C19 ‐Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations

Published:2019-11 Issue:3 Volume:107 Page:563-570
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Hicks J. Kevin¹^ORCID,Quilitz Rod E.²,Komrokji Rami S.³,Kubal Timothy E.³,Lancet Jeffrey E.³,Pasikhova Yanina²,Qin Dahui⁴,So Wonhee²,Caceres Gisela⁴,Kelly Kerry⁵,Salchert Yasmina S.⁴,Shahbazian Kevin¹,Abbas‐Aghababazadeh Farnoosh⁶,Fridley Brooke L.⁶,Velez Ana P.⁷,McLeod Howard L.¹^ORCID,Greene John N.⁷

Affiliation:

1. Department of Individualized Cancer Management H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA

2. Department of Pharmacy H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA

3. Department of Malignant Hematology H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA

4. Department of Pathology H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA

5. Department of Clinical Informatics H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA

6. Department of Biostatistics and Bioinformatics H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA

7. Department of Infectious Disease H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1641

Reference33 articles.

1. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM‐2004 study;Pagano L.;Haematologica,2006

2. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies

3. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia

4. Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry

5. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia;Maertens J.A.;J. Antimicrob. Chemother.,2018

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implementation and Evaluation Strategies for Pharmacogenetic Testing in Hospital Settings: A Scoping Review;Therapeutic Drug Monitoring;2024-09-11

2. Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections;European Journal of Clinical Pharmacology;2024-09-06

3. Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis;Frontiers in Pharmacology;2024-08-20

4. Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole;Clinical and Translational Science;2024-07

5. Implementation of a pharmacogenetic panel‐based test for pharmacotherapy‐based supportive care in an adult oncology clinic;Clinical and Translational Science;2024-07